Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
NANO MRNA Co., Ltd. Announces Strategic Alliance with SBI Securities and SBI Shinsei Corporate Investment
RUNX1 mRNA, a disease modifier for knee osteoarthritis: Study plan Approval for initiation of Phase 1 clinical trial
NANO MRNA, Apr-Jun (1Q) Ordinary Profit Loss Widens
RUNX1 mRNA, a disease modifier for knee osteoarthritis : Study plan submitted for initiation of Phase 1 clinical trial
TUG1 ASO for glioblastoma : Phase 1 clinical trial reaches final dosing level
[Delayed] We will exhibit at the Japan Pavilion during the 2025 BIO International Convention
NANO MRNA, Continue Net Income Turns to Loss
NANO MRNA, Apr-Dec (Cumulative 3Q) Net Income Loss Narrows, Oct-Dec Net Income Loss Narrows
NANO MRNA Co., Ltd., The Current Fiscal Year Net Income Loss to Narrow